A protracted war in the Middle East could reduce the availability of air defences for Ukraine, President Volodymyr Zelensky said, acknowledging potential ripple effects from the US-led bombing campaign in Iran. Washington has all but stopped providing military aid to Kyiv since President Donald Trump returned to the White House last year, but the US continues to sell weapons financed by Ukraine’s ...
A protracted war in the Middle East could reduce the availability of air defences for Ukraine, President Volodymyr Zelensky said, acknowledging potential ripple effects from the US-led bombing campaign in Iran. Washington has all but stopped providing military aid to Kyiv since President Donald Trump returned to the White House last year, but the US continues to sell weapons financed by Ukraine’s allies, mainly from Europe. Zelensky said that he had discussed military assistance with German...
~ Phoebe Wang Transitions from Board of Directors to Chief AI Officer, Deepening Nuvini’s Commitment to AI-Driven Growth ~NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer and operator of profitable B2B SaaS businesses across America and emerging markets, today announced the appointment of Phoebe Wang as Chief Artificia...
~ Phoebe Wang Transitions from Board of Directors to Chief AI Officer, Deepening Nuvini’s Commitment to AI-Driven Growth ~NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer and operator of profitable B2B SaaS businesses across America and emerging markets, today announced the appointment of Phoebe Wang as Chief Artificial Intelligence Officer (“CAIO”), effective March 2, 2026. Ms. Wang transitions from her role as a me
Allianz Global Investors is considering purchasing dollars after months betting against the US currency as the war in the Middle East revives its status as a haven asset. In the short term, there are “good reasons to buy the dollar,” said Greg Hirt , who helps oversee €580 billion ($679 billion) as chief investment officer of multiasset strategies at the European asset manager. The greenback climb...
Allianz Global Investors is considering purchasing dollars after months betting against the US currency as the war in the Middle East revives its status as a haven asset. In the short term, there are “good reasons to buy the dollar,” said Greg Hirt , who helps oversee €580 billion ($679 billion) as chief investment officer of multiasset strategies at the European asset manager. The greenback climbed to a three-week high against a basket of currencies on Monday after US President Donald Trump said the bombing campaign against Iran could last for weeks. “We still believe in the long-term story of de-dollarization, and the slow weakening of the dollar, but perhaps in the short term we may have to go back to a more neutral position,” Hirt said in an interview. Hirt’s view marks a shift from roughly a year ago, when Trump’s threats of aggressive tariffs prompted AllianzGI to shift into non-dollar assets, including in Europe and emerging-market nations. But with crude spiking the most in four years, the Iran crisis has turned the traditional correlation between the dollar and oil positive for the first time in three months. Read: Dollar Rallies as Oil’s Surge Curbs Bets on Fed Rate Cuts Betting against the dollar has become a crowded trade, meaning there’s plenty of potential for a near-term appreciation. The latest CFTC data show that speculative investors trimmed their short positions in the greenback last week, after pushing them to the highest in five years earlier last month. Meanwhile, Hirt said he’d turned a “bit more positive” on US Treasuries after they climbed last week when US stocks came under pressure. “I’m not saying we are back to where we were before, but this de-correlation is coming back,” Hirt said. A tighter energy market due to the conflict in the Middle East could have an inflationary impact that hits the euro zone and Japan hardest, Hirt said, as both rely heavily on imports to power their economies. That could complicate the outlook for interest ra...
Bank of America Corp (Symbol: BAC) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $48.11B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.25% yield, according to the most recent Dividend Channel ''Div
Bank of America Corp (Symbol: BAC) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $48.11B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.25% yield, according to the most recent Dividend Channel ''Div
Arbor Realty Trust Inc (Symbol: ABR) has been named as a Top 10 Real Estate Investment Trust (REIT), according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among REITs, ABR shares displayed both attractive valuation metric
Arbor Realty Trust Inc (Symbol: ABR) has been named as a Top 10 Real Estate Investment Trust (REIT), according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among REITs, ABR shares displayed both attractive valuation metric
PepsiCo Inc (Symbol: PEP) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.4% yield, as well as a superb track record of at least two decades of dividend growth, according to the m
PepsiCo Inc (Symbol: PEP) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.4% yield, as well as a superb track record of at least two decades of dividend growth, according to the m
Svetlana Borisova/iStock via Getty Images Thesis ANI Pharmaceuticals, Inc. ( ANIP ) has just reported a 4Q25 non-GAAP EPS of $2.33, a figure that beat consensus by about $0.35. Revenue came in at $247.1 million, rising 30% year-over-year and also exceeding expectations by about $16.07 million. The company also guided to a full-year adjusted non-GAAP gross margin of somewhere between 59.3% and 60.3...
Svetlana Borisova/iStock via Getty Images Thesis ANI Pharmaceuticals, Inc. ( ANIP ) has just reported a 4Q25 non-GAAP EPS of $2.33, a figure that beat consensus by about $0.35. Revenue came in at $247.1 million, rising 30% year-over-year and also exceeding expectations by about $16.07 million. The company also guided to a full-year adjusted non-GAAP gross margin of somewhere between 59.3% and 60.3%, but will continue applying a 26% tax rate to non-GAAP adjustments unless items are non-deductible. ANI also expects between 21.5 and 21.8 million shares outstanding for full-year adjusted non-GAAP diluted EPS calculations. We can also expect an annual GAAP effective tax rate of about 26% to 28%. Shares closed about 4% lower on the day of the call; however, the stock price in general has been on a bit of a downward slope over the last month or so. Since my previous coverage, shares are down about 10% and find themselves trading in the $73 range. I thought a lot of the figures on earnings were actually quite strong. We saw some record numbers and Cortrophin Gel growth. However, there were some areas of caution, which included Cortrophin being seasonally weaker in 1Q26 due to insurance reverifications, among other things, as I'll explain. Now, due to this, I feel it is best to downgrade to a hold rating. Financials overview I thought ANI delivered a pretty decent performance in both the 4Q25 and FY25. Now, the results were mainly driven by the rapid expansion of its Rare Disease portfolio. 4Q25 revenue hit a record $247.1 million, up nearly 30% year-over-year, while FY25 managed to reach $883.4 million, a very strong 43.8% increase. ANI Pharmaceuticals, Inc. The big contributor was, of course, Cortrophin Gel, whose quarterly revenue alone managed to jump 87.6% to $111.4 million, with full-year sales rising 75.6% to $347.8 million. It’s very nice to see this growth, and it would imply growth in patient starts and broader adoption across neurology, rheumatology, nephrology, a...
Oracle Corp. ’s health records division has lost multiple senior leaders in recent months while the company works to modernize its software in the face of steep customer loses. Executive Vice President Sanga Viswanathan and Senior Vice President Suhas Uliyar are leaving the firm, some workers were told last week, according to people who asked not to be identified because the departures hadn’t been...
Oracle Corp. ’s health records division has lost multiple senior leaders in recent months while the company works to modernize its software in the face of steep customer loses. Executive Vice President Sanga Viswanathan and Senior Vice President Suhas Uliyar are leaving the firm, some workers were told last week, according to people who asked not to be identified because the departures hadn’t been announced. The two were among the most senior product and engineering leaders of that division. Oracle’s health unit was built from the $28 billion acquisition of electronic medical records provider Cerner Corp. in 2022. Chairman Larry Ellison declared the deal would help fix many of the industry’s ills by updating notoriously dated systems and creating a major growth engine for Oracle, known for its database software. Since then, market share for the renamed Oracle Health has “substantially” declined, according to an August 2025 report from KLAS Research, an industry research firm. As of the end of 2024, customers representing just more than 20% of US hospital beds were using Oracle’s health records software. Its main competitor, Epic Systems Inc. , was used by customers representing over half of US hospital beds. Three additional senior vice presidents — Quais Taraki, Ofer Michael, and Max Romanenko — have left the unit recently. Each was an executive in the Oracle’s cloud infrastructure division before being moved into the acquired unit to help reshape it. Taraki and Romanenko went to EDB, a database software company. Oracle declined to comment on the departures, which haven’t been announced elsewhere. Over the last year, Oracle’s main focus has become expanding its cloud infrastructure business and building data centers to fulfill massive AI contracts with customers like OpenAI. Still, the company continues to speak publicly about its ambitious vision to improve health care technology. Oracle recently launched a tool to automatically transcribe clinical notes with AI. ...